Recursion Pharmaceuticals GAAP EPS of -$0.21 beats by $0.08, revenue of $35.54M beats by $10.98M
Source: SeekingAlpha
2026-02-25 06:32:25 ET
More on Recursion Pharmaceuticals
- Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
- Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates
- Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Recursion Pharmaceuticals Q4 2025 Earnings Preview
- Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes
Read the full article on Seeking Alpha
For further details see:
Recursion Pharmaceuticals GAAP EPS of -$0.21 beats by $0.08, revenue of $35.54M beats by $10.98M
Recursion Pharmaceuticals Inc.
NASDAQ: RXRX
RXRX Trading
4.52% G/L:
$3.405 Last:
9,334,431 Volume:
$3.35 Open:
RXRX Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 26, 2026 02:00:43 pm
Short Interest Near 35% Surrounds Recursion Pharmaceuticals Inc. (NASDAQ: RXRX)
RXRX Stock Data
$2,001,374,702
484,488,629
1.68%
137
N/A
Biotechnology & Life Sciences
Healthcare
US
Salt Lake City
